Article
Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.
Drugs in R&D - 1 Jan 2010
Nunes Teresa, Rocha José F, Vaz-da-Silva Manuel, Igreja Bruno, Wright Lyndon C, Falcão Amílcar, Almeida Luis, Soares-da-Silva Patricio
Abstract excerpt
BACKGROUND: Activation of the sympathetic nervous system is an important feature in hypertension and congestive heart failure. A strategy for directly modulating sympathetic nerve function is to reduce the biosynthesis of norepinephrine (noradrenaline) via inhibition of dopamine-β-hydroxylase (DβH). OBJECTIVE: To assess the safety, tolerability, and pharmacokinetics of etamicastat (BIA 5-453), a new DβH...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
